Pacific Biosciences of California (NASDAQ:PACB) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Pacific Biosciences of California (NASDAQ:PACB) from a sell rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

PACB has been the topic of a number of other reports. Barclays raised their price target on Pacific Biosciences of California from $1.25 to $2.00 and gave the company an “underweight” rating in a report on Thursday. Piper Sandler reaffirmed a “neutral” rating and issued a $3.00 price objective (up from $2.00) on shares of Pacific Biosciences of California in a research note on Thursday. UBS Group assumed coverage on Pacific Biosciences of California in a research report on Wednesday, September 9th. They set a “neutral” rating and a $1.35 target price for the company. Finally, Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Pacific Biosciences of California has an average rating of “Reduce” and an average price target of $2.09.

Pacific Biosciences of California Price Performance

Shares of PACB stock opened at $2.26 on Friday. The company has a market capitalization of $702.48 million, a price-to-earnings ratio of -5.38 and a beta of 2.21. Pacific Biosciences of California has a one year low of $1.07 and a one year high of $3.43. The company’s fifty day moving average price is $1.93 and its 200-day moving average price is $1.62.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $39.31 million. Pacific Biosciences of California had a negative net margin of 81.31% and a negative return on equity of 5,752.12%. Equities research analysts expect that Pacific Biosciences of California will post -0.51 earnings per share for the current fiscal year.

Insider Activity

In related news, insider James Gibson, II sold 661,815 shares of Pacific Biosciences of California stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the transaction, the insider owned 1,083,848 shares in the company, valued at approximately $3,370,767.28. This trade represents a 37.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1.13, for a total value of $30,409.43. Following the sale, the insider directly owned 2,705,853 shares in the company, valued at $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Pacific Biosciences of California

Institutional investors and hedge funds have recently modified their holdings of the stock. Choreo LLC purchased a new stake in Pacific Biosciences of California during the 3rd quarter valued at $27,000. Interchange Capital Partners LLC purchased a new position in Pacific Biosciences of California during the third quarter worth $28,000. StoneX Group Inc. purchased a new position in Pacific Biosciences of California during the third quarter worth $36,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Pacific Biosciences of California during the third quarter valued at $38,000. Finally, Corient Private Wealth LP bought a new position in Pacific Biosciences of California during the second quarter valued at $30,000.

Pacific Biosciences of California News Roundup

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: PacBio reported third-quarter revenue of $40.56 million, above the $39.31 million consensus, and a loss of $0.11 per share, narrower than the expected $0.13 loss. Coverage also highlighted clinical adoption and AI partnerships as sources of growth. Zacks Q3 results Q3 deep dive
• Positive Sentiment: Piper Sandler reaffirmed its Neutral rating but raised its price target to $3 from $2, indicating a more favorable valuation view. Piper Sandler rating
• Neutral Sentiment: The company announced CFO changes; the report provided no further detail on the transition’s expected impact. CFO changes
• Negative Sentiment: Management narrowed its 2026 revenue guidance to $155 million–$160 million. Analysts also pointed to falling gross margins and substantial cash burn, which raises concerns about the company’s financial position despite its target of cash-flow breakeven in 2028. Revenue guidance and breakeven target Q3 outlook analysis
• Negative Sentiment: Barclays lifted its price target to $2 from $1.25 but maintained an Underweight rating, signaling continued caution about the shares. Barclays rating

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.